Treatment of Mantle Cell Lymphoma in Asia: Updated Consensus from the Asian Lymphoma Study Group.

Authors

Jason Yongsheng Chan, Soon Thye Lim, Choon Kiat Ong, Koji Izutsu, Yuqin Song, Eric Tse, Gin Gin Gan, Jay Datukan, Priscilla Caguioa, Nia Novianti Siregar, Anna Mira Lubis, Suporn Chuncharunee, Do Huyen Nga, Noorainun Yusof, Chieh-Lin Jerry Teng, Dok Hyun Yoon, Won Seog Kim

Published in

Cancer research and treatment. Sep 09, 2026. Epub Sep 09, 2026.

Abstract

This paper reports up-to-date expert consensus from the Asian Lymphoma Study Group (ALSG) on treatment recommendations for mantle cell lymphoma (MCL) in Asia.
A closed session meeting of the ALSG was convened in August 2025 to discuss MCL management practices in Asia. Consensus recommendations from that meeting are summarized here, and take into consideration international guidelines, the current treatment landscape in Asia, and global and Asia-specific literature.
In Asia, effective MCL management is limited by difficulties in accessing Bruton's tyrosine kinase inhibitors (BTKi) and other novel agents. For patients with indolent and stage I/II disease, active surveillance and involved-site radiotherapy (with/without immunochemotherapy), respectively, can be considered. In advanced MCL, less intensive immunochemotherapy is recommended for elderly, unfit patients; young, fit patients typically receive aggressive cytarabine-based regimens prior to consolidation autologous hematopoietic stem cell transplantation (HSCT). If accessible, covalent BTKi (cBTKi) can be integrated into the first line, and clinical trial enrollment is strongly encouraged for patients with high-risk features. Rituximab maintenance with/without cBTKi is recommended following first-line treatment. In the relapsed/refractory (R/R) setting, cBTKi are more widely used, and novel agents like non-covalent BTKi and chimeric antigen receptor T-cell therapies can be considered where available. Allogeneic HSCT is an option for high-risk or R/R transplant-eligible patients.
These recommendations aim to guide MCL management in Asia. Given the heterogeneity of the disease, diverse healthcare systems, and variable treatment access across the region, there is no one-size-fits-all approach and resource-stratified approaches should be considered.

PMID:
42722392
Bibliographic data and abstract were imported from PubMed on 11 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.